METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE

• US 20160326182A1
• Filed: 04/27/2016
• Published: 11/10/2016
• Est. Priority Date: 04/27/2015
• Status: Active Grant

• Current Assignee: 3St Research LLC, Albany Molecular Research Incorporated
• Original Assignee: Waterville Valley Technologies, Inc.
• Inventors: Peltier, James, Surman, Matthew, Golden, Kathryn, Pasetto, Paolo, Jin, Xiaomin, Jiang, Xiaowu, Camara, Fatoumata
• Granted Patent: US 10,226,456 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine
• CPC Class Codes: A61K 47/542 Carboxylic acids, e.g. a fatty acid or an amino acid
• CPC Class Codes: C07D 489/08 Oxygen atom

Abstract

Abuse-resistant opioid compounds, drug delivery systems, pharmaceutical compositions comprising an opioid covalently bound to a chemical moiety are provided. Methods of delivering an active ingredient to a subject and methods of preventing opioid abuse are also provided.

Claims

1. An abuse-resistant opioid compound represented by Formula I:

O—

X_n 

 

(I)

wherein,

O is an opioid selected from the group consisting of oxycodone and oxymorphone;

each X is an independent chemical moiety that is safe for human consumption and is selected from the group consisting of an amino acid, a dipeptide, an α

-hydroxy acid, a dicarboxylic acid, and a fatty acid; and

n is from 1 to 10.

2. The abuse-resistant opioid compound of claim 1, wherein X comprises alanine, proline, camosine, lactic acid, mandelic acid, malic acid, tartaric acid, succinic acid, citric acid, sorbic acid, oleic acid, or stearic acid.

3. The abuse-resistant opioid compound of claim 1, wherein the abuse-resistant opioid compound is represented by Formula IV:

4. The abuse-resistant opioid compound of claim 3, wherein the abuse-resistant compound is selected from the group consisting of:

5. A drug delivery system, comprising an abuse-resistant opioid compound represented by Formula I:

O—

X_n 

 

(I)

wherein,

O is an opioid selected from the group consisting of oxycodone and oxymorphone;

each X is an independent chemical moiety that is safe for human consumption and is selected from the group consisting of an amino acid, a dipeptide, an α

-hydroxy acid, a dicarboxylic acid, and a fatty acid; and

n is from 1 to 10.

6. The drug delivery system of claim 5, wherein X comprises alanine, proline, camosine, lactic acid, mandelic acid, malic acid, tartaric acid, succinic acid, citric acid, sorbic acid, oleic acid, or stearic acid.

7. The drug delivery system of claim 5, wherein the abuse-resistant opioid compound is represented by Formula IV:

8. A pharmaceutical composition, comprising:

an abuse-resistant opioid compound; and

at least one pharmaceutical additive,

wherein the abuse-resistant opioid compound is represented by Formula I;

O—

X_n 

 

(I)

wherein,

O is an opioid selected from the group consisting of oxycodone and oxymorphone;

each X is an independent chemical moiety that is safe for human consumption and is selected from the group consisting of an amino acid, a dipeptide, an α

-hydroxy acid, a dicarboxylic acid, and a fatty acid; and

n is from 1 to 10.

9. The pharmaceutical composition of claim 8, wherein X comprises alanine, proline, camosine, lactic acid, mandelic acid, malic acid, tartaric acid, succinic acid, citric acid, sorbic acid, oleic acid, or stearic acid.

10. The pharmaceutical composition of claim 8, wherein the abuse-resistant opioid compound is represented by Formula IV:

11. A method of delivering an active ingredient to a subject, comprising administering a therapeutically effective amount of an abuse-resistant opioid compound to a subject in need thereof,

wherein the abuse-resistant opioid compound is represented by Formula I:

O—

X_n 

 

(I)

wherein,

O is an opioid selected from the group consisting of oxycodone and oxymorphone;

each X is an independent chemical moiety that is safe for human consumption and is selected from the group consisting of an amino acid, a dipeptide, an α

-hydroxy acid, a dicarboxylic acid, and a fatty acid; and

n is from 1 to 10.

12. The method of claim 11, wherein X comprises alanine, proline, camosine, lactic acid, mandelic acid, malic acid, tartaric acid, succinic acid, citric acid, sorbic acid, oleic acid, or stearic acid.

13. The method of claim 11, wherein the abuse-resistant opioid compound is represented by Formula IV:

14. A method of preventing opioid abuse, comprising administering a therapeutically effective amount of an abuse-resistant opioid compound to a subject in need thereof,

wherein the abuse-resistant opioid compound is represented by Formula I:

O—

X_n 

 

(I)

wherein,

O is an opioid selected from the group consisting of oxycodone and oxymorphone;

each X is an independent chemical moiety that is safe for human consumption and is selected from the group consisting of an amino acid, a dipeptide, an α

-hydroxy acid, a dicarboxylic acid, and a fatty acid; and

n is from 1 to 10.

15. The method of claim 14, wherein X comprises alanine, proline, camosine, lactic acid, mandelic acid, malic acid, tartaric acid, succinic acid, citric acid, sorbic acid, oleic acid, or stearic acid.

16. The method of claim 14, wherein the abuse-resistant opioid compound is represented by Formula IV: